You are here

  • Home
  • Archive
  • Volume 92, Issue 5
  • It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease

Article Text

Article menu
Download PDFPDF
Editorial commentary
It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease
  1. Nils Koch-Henriksen1,2
  1. 1 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
  2. 2 The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Copenhagen, Denmark
  1. Correspondence to Dr Nils Koch-Henriksen, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus DK9100, Denmark; koch-henriksen{at}stofanet.dk

https://doi.org/10.1136/jnnp-2020-325684

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The first disease modifying treatments (DMT) of multiple sclerosis (MS) were introduced in the 1990s, and since then numerous new drugs have emerged. Tailoring the treatment in the individual patients with MS is difficult and requires detailed knowledge of the efficacy and risks of all available preparations. Comparing different drugs alone from their effects over placebo or first-generation drugs in the randomised controlled trials is problematic because these studies have been applied to different MS populations, and although there has been a certain harmony in inclusion criteria between such studies, the natural selection of study candidates from the different background MS populations may vary considerably. The many available DMTs enable preparation …

    View Full Text

    Footnotes

    • Contributors NK-H solely authored this editorial.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests NK-H has within 2 years received support for participation in congresses and symposia by SG.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles